SCHEMBL563323

SCHEMBL563323

O=C1Cc2ccccc2Cc2sccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
HPGD P15428 5/20 0.47
KDM4E B2RXH2 4/20 0.47
CES1 P23141 2/20 0.45
BCHE P06276 1/20 0.45
DRD1 P21728 3/20 0.43
DRD3 P35462 3/20 0.43
HRH1 P35367 2/20 0.43
HRH4 Q9H3N8 2/20 0.43
DRD2 P14416 2/20 0.43
DRD4 P21917 2/20 0.43
DRD5 P21918 2/20 0.43
CYP1A2 P05177 2/20 0.43
LMNA P02545 2/20 0.42
CYP3A4 P08684 2/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
ADRA2A P08913 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2430216 0.77 DRD1 (0.43) ALDH1A1HPGDKDM4ECES1BCHE
SCHEMBL29940483 0.77 DRD1 (0.43) ALDH1A1HPGDKDM4ECES1BCHE
SCHEMBL7411028 0.74 AHR (0.52) KDM4ECES1DRD1DRD3HRH1
SCHEMBL1472457 0.73 ALDH1A1 (0.62) ALDH1A1HPGDKDM4ECES1BCHE
SCHEMBL14441607 0.72 CYP1A2 (0.67) ALDH1A1HPGDKDM4ECES1BCHE
SCHEMBL31392781 0.72 CYP1A2 (0.67) ALDH1A1HPGDKDM4ECES1BCHE
SCHEMBL9409761 0.72 HRH1 (0.47) ALDH1A1HPGDKDM4ECES1BCHE
SCHEMBL30310960 0.72 HRH1 (0.47) ALDH1A1HPGDKDM4ECES1BCHE
SCHEMBL31392106 0.72 CES1 (0.67) ALDH1A1HPGDKDM4ECES1BCHE
SCHEMBL3638469 0.72 CES1 (0.67) ALDH1A1HPGDKDM4ECES1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404729-B2 Heterocyclic tetracyclic tetrahydrofuran derivatives JANSSEN PHARMACEUTICA, NV (BE) 2013-03-26 US disclosed
US-20120238563-A1 NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES CID-NUNEZ JOSE MARIA (ES) 2012-09-20 US disclosed
US-20120035170-A1 NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES NUNEZ JOSE MARIA (ES) 2012-02-09 US disclosed
US-8022102-B2 Unsaturated tetracyclic tetrahydrofuran derivatives JANSSEN PHARMACEUTICA, NV (BE) 2011-09-20 US disclosed
US-20110144094-A1 HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES CID-NUNEZ JOSE MARIA 2011-06-16 US disclosed
US-20110144094-A1 HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES CID-NUNEZ JOSE MARIA 2011-06-16 US disclosed
US-7915249-B2 serotonin 5-HT2A, 5-HT2C and dopamin D2 receptors antagonist, and norepinephrine reuptake inhibitor; antidepressant, anxiolytic agent; psychosis, schizophrenia, bipolar and sexual disorders, obesity JANSSEN PHARMACEUTICAL NV (BE) 2011-03-29 US disclosed
US-20080108599-A1 Heterocyclic Tetracyclic Tetrahydrofuran Derivatives As 5Ht2 Inhibitors In The Treatment Of Cns Disorders JANSSEN-CILAG S.A. (ES) 2008-05-08 US disclosed
US-20070191469-A1 Novel tetracyclic tetrahydrofuran derivatives JANSSEN-CILAG S.A. (ES) 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035170-A1 NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES HTR2C, HTR2A, HTR1A ALDH1A1 287/4885HPGD 399/4885KDM4E 4791/4885
US-20080108599-A1 Heterocyclic Tetracyclic Tetrahydrofuran Derivatives As 5Ht2 Inhibitors In The Treatment Of Cns Disorders HTR2C, HTR2A, TPH2 ALDH1A1 580/4885HPGD 620/4885KDM4E 4647/4885
US-20070191469-A1 Novel tetracyclic tetrahydrofuran derivatives HTR2C, HTR2A, HTR1A ALDH1A1 349/4885HPGD 620/4885KDM4E 4793/4885
US-20110144094-A1 HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES HTR2C, HTR2A, HTR5A ALDH1A1 346/4885HPGD 444/4885KDM4E 4710/4885
US-20120238563-A1 NOVEL UNSATURATED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES HTR2C, HTR2A, HTR1A ALDH1A1 287/4885HPGD 399/4885KDM4E 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.